169 related articles for article (PubMed ID: 24490882)
1. Specificity of regulatory T cells that modulate vascular inflammation.
Franco A; Touma R; Song Y; Shimizu C; Tremoulet AH; Kanegaye JT; Burns JC
Autoimmunity; 2014 Mar; 47(2):95-104. PubMed ID: 24490882
[TBL] [Abstract][Full Text] [Related]
2. Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease.
Burns JC; Touma R; Song Y; Padilla RL; Tremoulet AH; Sidney J; Sette A; Franco A
Autoimmunity; 2015 May; 48(3):181-8. PubMed ID: 25822882
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin induces IgG internalization by tolerogenic myeloid dendritic cells that secrete IL-10 and expand Fc-specific regulatory T cells.
Hsieh LE; Song J; Tremoulet AH; Burns JC; Franco A
Clin Exp Immunol; 2022 Jun; 208(3):361-371. PubMed ID: 35536993
[TBL] [Abstract][Full Text] [Related]
4. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease.
Guo MM; Tseng WN; Ko CH; Pan HM; Hsieh KS; Kuo HC
Allergy; 2015 Mar; 70(3):310-8. PubMed ID: 25585854
[TBL] [Abstract][Full Text] [Related]
5. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.
Burns JC; Song Y; Bujold M; Shimizu C; Kanegaye JT; Tremoulet AH; Franco A
Clin Exp Immunol; 2013 Dec; 174(3):337-44. PubMed ID: 23901839
[TBL] [Abstract][Full Text] [Related]
6. High Dose Intravenous IgG Therapy Modulates Multiple NK Cell and T Cell Functions in Patients With Immune Dysregulation.
McAlpine SM; Roberts SE; Heath JJ; Käsermann F; Issekutz AC; Issekutz TB; Derfalvi B
Front Immunol; 2021; 12():660506. PubMed ID: 34093549
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T cell microRNA expression changes in children with acute Kawasaki disease.
Ni FF; Li CR; Li Q; Xia Y; Wang GB; Yang J
Clin Exp Immunol; 2014 Nov; 178(2):384-93. PubMed ID: 25039241
[TBL] [Abstract][Full Text] [Related]
8. Single-cell RNA sequencing of peripheral blood mononuclear cells from acute Kawasaki disease patients.
Wang Z; Xie L; Ding G; Song S; Chen L; Li G; Xia M; Han D; Zheng Y; Liu J; Xiao T; Zhang H; Huang Y; Li Y; Huang M
Nat Commun; 2021 Sep; 12(1):5444. PubMed ID: 34521850
[TBL] [Abstract][Full Text] [Related]
9. Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Coronavirus Disease-19 Associated Multisystem Inflammatory Syndrome in Children.
Chen MR; Kuo HC; Lee YJ; Chi H; Li SC; Lee HC; Yang KD
Front Immunol; 2021; 12():632890. PubMed ID: 33732254
[TBL] [Abstract][Full Text] [Related]
10. Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis.
Thiruppathi M; Sheng JR; Li L; Prabhakar BS; Meriggioli MN
J Autoimmun; 2014 Aug; 52():64-73. PubMed ID: 24388113
[TBL] [Abstract][Full Text] [Related]
11. Immune Regulatory Functions of IgG in the Ontogeny of Human Natural Regulatory T Cells.
Franco A
Crit Rev Immunol; 2022; 42(2):29-33. PubMed ID: 37017286
[TBL] [Abstract][Full Text] [Related]
12. The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease.
Burns JC; Franco A
Expert Rev Clin Immunol; 2015; 11(7):819-25. PubMed ID: 26099344
[TBL] [Abstract][Full Text] [Related]
13. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[TBL] [Abstract][Full Text] [Related]
14. Altered immunoglobulin A and M levels associated with changes in BAFF and APRIL after administration of intravenous immunoglobulin to treat Kawasaki disease.
Doi M; Takeda T; Sakurai Y; Kato J; Hayashi T; Fukuda K; Takase T; Shima M
J Investig Allergol Clin Immunol; 2010; 20(5):413-8. PubMed ID: 20945608
[TBL] [Abstract][Full Text] [Related]
15. Expression of FcRs on monocytes among Kawasaki disease patients with coronary artery lesions.
Xia Y; Tian X; Li Q; Wang G; Li C; Yang J
Int Immunopharmacol; 2017 Apr; 45():1-5. PubMed ID: 28147297
[TBL] [Abstract][Full Text] [Related]
16. Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.
Ge X; Li CR; Yang J; Wang GB
Scand J Immunol; 2013 May; 77(5):389-97. PubMed ID: 23298273
[TBL] [Abstract][Full Text] [Related]
17. Infliximab regulates monocytes and regulatory T cells in Kawasaki disease.
Koizumi K; Hoshiai M; Katsumata N; Toda T; Kise H; Hasebe Y; Kono Y; Sunaga Y; Yoshizawa M; Watanabe A; Kagami K; Abe M; Sugita K
Pediatr Int; 2018 Sep; 60(9):796-802. PubMed ID: 29543362
[TBL] [Abstract][Full Text] [Related]
18. Increased frequency of immunoglobulin (Ig)A-secreting cells following Toll-like receptor (TLR)-9 engagement in patients with Kawasaki disease.
Giordani L; Quaranta MG; Marchesi A; Straface E; Pietraforte D; Villani A; Malorni W; Del Principe D; Viora M
Clin Exp Immunol; 2011 Mar; 163(3):346-53. PubMed ID: 21175593
[TBL] [Abstract][Full Text] [Related]
19. Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease.
Inoue T; Murakami S; Matsumoto K; Matsuda A
Pediatr Rheumatol Online J; 2020 Oct; 18(1):76. PubMed ID: 33023630
[TBL] [Abstract][Full Text] [Related]
20. Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance.
Fury W; Tremoulet AH; Watson VE; Best BM; Shimizu C; Hamilton J; Kanegaye JT; Wei Y; Kao C; Mellis S; Lin C; Burns JC
Hum Immunol; 2010 Sep; 71(9):865-73. PubMed ID: 20600450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
